G R Seage 3rd
Overview
Explore the profile of G R Seage 3rd including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
51
Citations
1256
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Decker M, Seage 3rd G, Hemenway D, Gupta J, Raj A, Silverman J
Sex Transm Infect
. 2009 Jul;
85(7):555-60.
PMID: 19625287
Background: The estimated one in three women worldwide victimized by intimate partner violence (IPV) consistently demonstrate elevated STI/HIV prevalence, with their abusive male partners' risky sexual behaviours and subsequent infection...
2.
Novitsky V, Woldegabriel E, Wester C, McDonald E, Rossenkhan R, Ketunuti M, et al.
AIDS Care
. 2008 Jul;
20(7):806-11.
PMID: 18608056
Methods for identification of primary HIV infections seem increasingly important to understand pathogenesis, and to prevent transmission, which is particularly efficient during acute infection. Most current algorithms for HIV testing...
3.
Murphy D, Hoffman D, Seage 3rd G, Belzer M, Xu J, Durako S, et al.
AIDS Care
. 2007 Feb;
19(1):42-51.
PMID: 17265577
A simplified version of the HIVNET prototype HIV vaccine process was developed for adolescents at risk of HIV by:(1) reducing reading level; (2) reorganizing; (3) adding illustrations; and (4) obtaining...
4.
Losina E, Anglaret X, Yazdanpanah Y, Wang B, Toure S, Seage 3rd G, et al.
S Afr Med J
. 2006 Jul;
96(6):526-9.
PMID: 16841136
Objective: To estimate incidence rates of opportunistic diseases (ODs) and mortality for patients with and without a history of OD among HIV-infected patients in Côte d'Ivoire. Methods: Using incidence density...
5.
Gortmaker S, Hughes M, Cervia J, Brady M, JOHNSON G, Seage 3rd G, et al.
N Engl J Med
. 2002 Jan;
345(21):1522-8.
PMID: 11794218
Background: Combination therapy including protease inhibitors has been shown to be effective in treating adults infected with human immunodeficiency virus type 1 (HIV-1), but there are only limited data regarding...
6.
Buchacz K, Cervia J, Lindsey J, Hughes M, Seage 3rd G, Dankner W, et al.
Pediatrics
. 2001 Oct;
108(4):E72.
PMID: 11581480
Objective: To examine beneficial or detrimental effects of protease inhibitor (PI)-containing antiretroviral regimens on height and weight growth in children with human immunodeficiency virus (HIV) infection. Methods: A prospective cohort...
7.
Marmor M, Sheppard H, Donnell D, Bozeman S, Celum C, Buchbinder S, et al.
J Acquir Immune Defic Syndr
. 2001 Aug;
27(5):472-81.
PMID: 11511825
Objective: To investigate evidence for resistance to HIV-1 infection associated with the heterozygous genotype CCR5-+/Delta32 and with the homozygous genotype CCR5-Delta32/Delta32, which results in a nonfunctional CCR5 receptor. Design: Cohort...
8.
Yazdanpanah Y, Chene G, Losina E, Goldie S, Merchadou L, Alfandari S, et al.
Int J Epidemiol
. 2001 Aug;
30(4):864-71.
PMID: 11511618
Background: Clinical guidelines for the prevention of opportunistic infections in human immunodeficiency virus (HIV)-infected individuals have been developed on the basis of natural history data collected in the USA. The...
9.
Seage 3rd G, Holte S, Metzger D, Koblin B, Gross M, Celum C, et al.
Am J Epidemiol
. 2001 Apr;
153(7):619-27.
PMID: 11282787
Questions exist about whether testing of preventive human immunodeficiency virus (HIV)-1 vaccines, which will require rapid recruitment and retention of cohorts with high HIV-1 seroincidence, is feasible in the United...
10.
Paltiel A, Goldie S, Losina E, Weinstein M, Seage 3rd G, Kimmel A, et al.
Clin Infect Dis
. 2001 Mar;
32(5):783-93.
PMID: 11229847
We developed a mathematical simulation model to anticipate outcomes from an upcoming trial of targeted, preemptive cytomegalovirus (CMV) therapy in high-risk, human immunodeficiency virus (HIV)-infected patients identified by means of...